董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Lance G. Laing | 男 | Director, Chief Science Officer, Vice President and Secretary | 59 | 43.09万美元 | 未持股 | 2021-03-31 |
| Richard E. Buller | 男 | Director | 71 | 8.09万美元 | 未持股 | 2021-03-31 |
| Leo T. Furcht | 男 | Director | 74 | 8.00万美元 | 未持股 | 2021-03-31 |
| Brian F. Sullivan | 男 | Chairman of the Board and Chief Executive Officer | 59 | 46.90万美元 | 未持股 | 2021-03-31 |
| David F. Dalvey | 男 | Director | 62 | 8.00万美元 | 未持股 | 2021-03-31 |
| Richard J. Nigon | 男 | Director | 73 | 8.00万美元 | 未持股 | 2021-03-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Vicky Hahne | 女 | Chief Financial Officer | 55 | 22.44万美元 | 未持股 | 2021-03-31 |
| Lance G. Laing | 男 | Director, Chief Science Officer, Vice President and Secretary | 59 | 43.09万美元 | 未持股 | 2021-03-31 |
| Brian F. Sullivan | 男 | Chairman of the Board and Chief Executive Officer | 59 | 46.90万美元 | 未持股 | 2021-03-31 |
董事简历
中英对照 | 中文 | 英文- Lance G. Laing
-
LanceG.Laing是我们的联合创始人，自2012年我们开始运营以来一直担任首席科学官，Vice President，秘书和董事。Laing博士的职业生涯跨度超过15年，从事药物发现研究和技术开发。他在约翰霍普金斯大学（Johns Hopkins University）获得生物物理学和生物化学博士学位，并在华盛顿大学医学院（Washington University Medical School）完成了美国国立卫生研究院博士后奖学金。他已获得19项美国专利，另有24项正在申请的美国专利。他的药物发现研究生涯始于诺华收购的ScriptGen/Anadys Pharmaceuticals，在那里他在Peter Kim教授（后来成为默克研究总裁）手下工作。他还担任两家公司的化学和生物应用主任以及检测产品开发主任，这两家公司各自开发了类似于Celcuity用于执行Celsignia测试的仪器。他在这两家仪器公司的工作使他在为这些仪器开发各种专利申请方面拥有独特的专业知识和经验。最近，他曾担任国际药物发现和开发公司的执行董事。
Lance G. Laing is our co-founder and has served as Chief Science Officer, Vice President, Secretary and a director since we commenced operations in 2012. Dr. Laing’s career spans more than 15 years in drug discovery research and technology development. He received his doctorate in biophysics and biochemistry from The Johns Hopkins University and completed a National Institutes of Health post-doctoral fellowship at Washington University Medical School. He has received 19 U.S. patents and has an additional 24 U.S. patents pending. His drug discovery research career began at Scriptgen/Anadys Pharmaceuticals purchased by Novartis, where he worked under Professor Peter Kim, who became President of Merck Research. He also was Director of Chemistry and Bioapplications and Director of Detection Product Development for two companies that each developed instruments similar to those Celcuity uses to perform the CELsignia tests. His work at these two instrument companies gave him unique expertise and experience in developing a variety of patented applications for these instruments. Most recently, he served as an executive director for an international drug discovery and development company. - LanceG.Laing是我们的联合创始人，自2012年我们开始运营以来一直担任首席科学官，Vice President，秘书和董事。Laing博士的职业生涯跨度超过15年，从事药物发现研究和技术开发。他在约翰霍普金斯大学（Johns Hopkins University）获得生物物理学和生物化学博士学位，并在华盛顿大学医学院（Washington University Medical School）完成了美国国立卫生研究院博士后奖学金。他已获得19项美国专利，另有24项正在申请的美国专利。他的药物发现研究生涯始于诺华收购的ScriptGen/Anadys Pharmaceuticals，在那里他在Peter Kim教授（后来成为默克研究总裁）手下工作。他还担任两家公司的化学和生物应用主任以及检测产品开发主任，这两家公司各自开发了类似于Celcuity用于执行Celsignia测试的仪器。他在这两家仪器公司的工作使他在为这些仪器开发各种专利申请方面拥有独特的专业知识和经验。最近，他曾担任国际药物发现和开发公司的执行董事。
- Lance G. Laing is our co-founder and has served as Chief Science Officer, Vice President, Secretary and a director since we commenced operations in 2012. Dr. Laing’s career spans more than 15 years in drug discovery research and technology development. He received his doctorate in biophysics and biochemistry from The Johns Hopkins University and completed a National Institutes of Health post-doctoral fellowship at Washington University Medical School. He has received 19 U.S. patents and has an additional 24 U.S. patents pending. His drug discovery research career began at Scriptgen/Anadys Pharmaceuticals purchased by Novartis, where he worked under Professor Peter Kim, who became President of Merck Research. He also was Director of Chemistry and Bioapplications and Director of Detection Product Development for two companies that each developed instruments similar to those Celcuity uses to perform the CELsignia tests. His work at these two instrument companies gave him unique expertise and experience in developing a variety of patented applications for these instruments. Most recently, he served as an executive director for an international drug discovery and development company.
- Richard E. Buller
-
RichardE.Buller于2019年12月被任命为Celcuity的董事会成员。Buller博士在主要制药公司领导肿瘤学临床开发和转化医学部门拥有超过15年的经验。他曾参与获得美国FDA批准的15种药物和几种伴随诊断的开发。Buller博士最近担任辉瑞公司（Pfizer，Inc.）肿瘤临床开发和转化肿瘤学Vice President，该公司是全球最大的制药公司之一，直到2016年退休。他此前曾担任Exelixis公司（领先的生物制药公司）的转化医学Vice President，在那里他曾领导研究通过分子测试选择的患者，以纳入他们的2期和3期临床试验。他的制药公司职业生涯始于任职GlaxoSmithKline公司，担任肿瘤医学发展中心的董事。担任药物开发领导职务之前，他曾担任the University of Iowa的妇科肿瘤学教授，在那里他曾领导实验室研究，专注于识别涉及卵巢癌的基因组变体。他获得贝勒医学院（the Baylor College of Medicine）的医学博士学位，在那里他也获得细胞生物学博士学位。
Richard E. Buller, was appointed to Celcuity’s Board in December 2019. Dr. Buller has over 15 years of experience leading oncology clinical development and translational medicine departments at major pharmaceutical companies. He has participated in the development of 15 drugs and several companion diagnostics that received U.S. FDA approval. Dr. Buller most recently served as Head Oncology Clinical Development and Vice President of Translational Oncology at Pfizer, Inc, one of the world’s largest pharmaceutical companies, until he retired in 2016. He had previously served as Vice President of Translational Medicine at Exelixis, a leading biopharmaceutical company, where he led efforts to study patients selected by molecular testing for inclusion in their phase 2 and phase 3 clinical trials. He began his pharmaceutical company career at GlaxoSmithKline as Director of the Oncology Medicine Development Center. Prior to his leadership positions in drug development, he was Professor of Gynecologic Oncology at the University of Iowa, where he led laboratory research focused on identifying genomic variants involved in ovarian cancer. He received his M.D. from the Baylor College of Medicine, where he also received his Ph.D. in cell biology. - RichardE.Buller于2019年12月被任命为Celcuity的董事会成员。Buller博士在主要制药公司领导肿瘤学临床开发和转化医学部门拥有超过15年的经验。他曾参与获得美国FDA批准的15种药物和几种伴随诊断的开发。Buller博士最近担任辉瑞公司（Pfizer，Inc.）肿瘤临床开发和转化肿瘤学Vice President，该公司是全球最大的制药公司之一，直到2016年退休。他此前曾担任Exelixis公司（领先的生物制药公司）的转化医学Vice President，在那里他曾领导研究通过分子测试选择的患者，以纳入他们的2期和3期临床试验。他的制药公司职业生涯始于任职GlaxoSmithKline公司，担任肿瘤医学发展中心的董事。担任药物开发领导职务之前，他曾担任the University of Iowa的妇科肿瘤学教授，在那里他曾领导实验室研究，专注于识别涉及卵巢癌的基因组变体。他获得贝勒医学院（the Baylor College of Medicine）的医学博士学位，在那里他也获得细胞生物学博士学位。
- Richard E. Buller, was appointed to Celcuity’s Board in December 2019. Dr. Buller has over 15 years of experience leading oncology clinical development and translational medicine departments at major pharmaceutical companies. He has participated in the development of 15 drugs and several companion diagnostics that received U.S. FDA approval. Dr. Buller most recently served as Head Oncology Clinical Development and Vice President of Translational Oncology at Pfizer, Inc, one of the world’s largest pharmaceutical companies, until he retired in 2016. He had previously served as Vice President of Translational Medicine at Exelixis, a leading biopharmaceutical company, where he led efforts to study patients selected by molecular testing for inclusion in their phase 2 and phase 3 clinical trials. He began his pharmaceutical company career at GlaxoSmithKline as Director of the Oncology Medicine Development Center. Prior to his leadership positions in drug development, he was Professor of Gynecologic Oncology at the University of Iowa, where he led laboratory research focused on identifying genomic variants involved in ovarian cancer. He received his M.D. from the Baylor College of Medicine, where he also received his Ph.D. in cell biology.
- Leo T. Furcht
-
LeoT.Furcht于2019年5月被任命为Celcuity的董事会成员。Furcht博士目前是明尼苏达大学（University of Minnesota）的Allen-Pardee癌症生物学教授和实验室医学和病理学系主任，也是分子病理学和基因组学部门的成员。他曾担任University of Minnesota Physicians（医学院执业计划，约有700名医生）的董事会主席（从2004年到2014年）。他也曾担任the Biomedical Engineering Center的创始董事（从1990年到2001年），在那里他曾领导明尼苏达大学（the University of Minnesota）建立干细胞和分子诊断专业知识。他发表了180多篇科学论文，在多肽、生物材料、成人干细胞领域拥有30多项专利。他的业务经验包括共同创立两家医疗技术公司，South Bay Medical公司（医疗设备公司，被Mentor Corporation收购），以及Diascreen公司（诊断公司，后来被Chronimed公司收购）。
Leo T. Furcht, was appointed to Celcuity’s Board in May 2019. Dr. Furcht is currently Allen-Pardee Professor of Cancer Biology and Head of the Department of Laboratory Medicine and Pathology at the University of Minnesota and a member of the Division of Molecular Pathology and Genomics. He served as Chairman of the Board of Directors for University of Minnesota Physicians, the Medical School practice plan with approximately 700 physicians, from 2004-2014. He was also the founding Director of the Biomedical Engineering Center from 1990-2001 where he led efforts to establish stem cell and molecular diagnostics expertise at the University of Minnesota. He has published more than 180 scientific papers and holds more than 30 patents in the fields of polypeptides, biomaterials, and adult stem cells. His business experience includes co-founding two medical technology companies, South Bay Medical, a medical device company that was acquired by Mentor Corporation, and Diascreen, a diagnostics company, which was later acquired by Chronimed. - LeoT.Furcht于2019年5月被任命为Celcuity的董事会成员。Furcht博士目前是明尼苏达大学（University of Minnesota）的Allen-Pardee癌症生物学教授和实验室医学和病理学系主任，也是分子病理学和基因组学部门的成员。他曾担任University of Minnesota Physicians（医学院执业计划，约有700名医生）的董事会主席（从2004年到2014年）。他也曾担任the Biomedical Engineering Center的创始董事（从1990年到2001年），在那里他曾领导明尼苏达大学（the University of Minnesota）建立干细胞和分子诊断专业知识。他发表了180多篇科学论文，在多肽、生物材料、成人干细胞领域拥有30多项专利。他的业务经验包括共同创立两家医疗技术公司，South Bay Medical公司（医疗设备公司，被Mentor Corporation收购），以及Diascreen公司（诊断公司，后来被Chronimed公司收购）。
- Leo T. Furcht, was appointed to Celcuity’s Board in May 2019. Dr. Furcht is currently Allen-Pardee Professor of Cancer Biology and Head of the Department of Laboratory Medicine and Pathology at the University of Minnesota and a member of the Division of Molecular Pathology and Genomics. He served as Chairman of the Board of Directors for University of Minnesota Physicians, the Medical School practice plan with approximately 700 physicians, from 2004-2014. He was also the founding Director of the Biomedical Engineering Center from 1990-2001 where he led efforts to establish stem cell and molecular diagnostics expertise at the University of Minnesota. He has published more than 180 scientific papers and holds more than 30 patents in the fields of polypeptides, biomaterials, and adult stem cells. His business experience includes co-founding two medical technology companies, South Bay Medical, a medical device company that was acquired by Mentor Corporation, and Diascreen, a diagnostics company, which was later acquired by Chronimed.
- Brian F. Sullivan
-
Brian F. Sullivan，于2005年担任Entegris, Inc.公司董事会成员。2003年12月至公司兼并后，他担任Entegris Minnesota主管及该公司薪酬和股票期权委员会成员，公司兼并后，一直到2008年5月加入审计和财务委员会期间，他担任管理层发展和薪酬委员会成员。他于2012年联合创立生物技术公司Celcuity LLC，并担任该公司主席和CEO。2002年起他担任SterilMed, Inc公司主席和CEO，直至2011年他从该公司退休，该公司同时于2011年被Johnson & Johnson公司收购。他于1986年联合创立Recovery Engineering, Inc.公司，并担任主席和CEO，直至该公司1999年被Proctor & Gamble Co。收购。他于2008年担任Virtual Radiologic Corporation董事会成员，直至该公司2010年被收购。他还担任多家私人公司和非盈利机构的董事会成员。他在哈佛大学（Harvard University）获得学士学位。
Brian F. Sullivan is our co-founder and has served as Chairman of the Board and Chief Executive Officer since we commenced operations in 2012. Mr. Sullivan has over 25 years of experience founding and building successful, high growth technology companies. He was Chairman and CEO of SterilMed, a medical device reprocessing company, from 2003 when he led an investment group to acquire a majority interest, until its sale to Ethicon Endo-Surgery Inc., a Johnson & Johnson company, for $330 million in 2011. Previously, he was co-founder and Chief Executive Officer of Recovery Engineering, a filtration company, which he took public and subsequently sold to Procter & Gamble for $265 million in 1999. Since 2003 Mr. Sullivan has served on the board of directors of Entegris, Inc., a publicly-held company. Mr. Sullivan has received seven U.S. patents and has several patents pending. He graduated magna cum laude with distinction from Harvard College with an A.B. in economics. - Brian F. Sullivan，于2005年担任Entegris, Inc.公司董事会成员。2003年12月至公司兼并后，他担任Entegris Minnesota主管及该公司薪酬和股票期权委员会成员，公司兼并后，一直到2008年5月加入审计和财务委员会期间，他担任管理层发展和薪酬委员会成员。他于2012年联合创立生物技术公司Celcuity LLC，并担任该公司主席和CEO。2002年起他担任SterilMed, Inc公司主席和CEO，直至2011年他从该公司退休，该公司同时于2011年被Johnson & Johnson公司收购。他于1986年联合创立Recovery Engineering, Inc.公司，并担任主席和CEO，直至该公司1999年被Proctor & Gamble Co。收购。他于2008年担任Virtual Radiologic Corporation董事会成员，直至该公司2010年被收购。他还担任多家私人公司和非盈利机构的董事会成员。他在哈佛大学（Harvard University）获得学士学位。
- Brian F. Sullivan is our co-founder and has served as Chairman of the Board and Chief Executive Officer since we commenced operations in 2012. Mr. Sullivan has over 25 years of experience founding and building successful, high growth technology companies. He was Chairman and CEO of SterilMed, a medical device reprocessing company, from 2003 when he led an investment group to acquire a majority interest, until its sale to Ethicon Endo-Surgery Inc., a Johnson & Johnson company, for $330 million in 2011. Previously, he was co-founder and Chief Executive Officer of Recovery Engineering, a filtration company, which he took public and subsequently sold to Procter & Gamble for $265 million in 1999. Since 2003 Mr. Sullivan has served on the board of directors of Entegris, Inc., a publicly-held company. Mr. Sullivan has received seven U.S. patents and has several patents pending. He graduated magna cum laude with distinction from Harvard College with an A.B. in economics.
- David F. Dalvey
-
David F. Dalvey，他在公司金融和风险投资方面有28年的经验，主要就职于以发展为导向的技术公司。2008年9月至今，他担任Mount Yale Venture Fund, L.P。的管理合伙人， 该公司是一家管理公司，投资高层风险投资基金和其他资产；2000年9月至今，担任风险投资管理公司Brightstone Capita的普通合伙人。此前，1995至2000年，他在R.J. Steichen and Company担任管理职位；1992至1995年，在风险投资公司The Food Fund LP担任管理职位；1987至1992年，在投资银行Wessels, Arnold & Henderson担任管理职位。他有丰富的运营经验，曾担任多家私人公司的董事会成员或顾问，包括担任Definity Health, Inc. （直到出售给United Health Group）， NatureVision, Inc. （直到首次公开募股） 和Agiliti, Inc. （直到出售给VeriCenter, Inc./SunGard Services）的董事。目前，他担任Blue Rock Market Neutral Fund的独立董事和审计委员会成员， 该公司是在1940年投资公司法注册的共有基金；并担任Digitiliti, Inc. （OTC：DIGI.PK）的董事，该公司提供计算机数据管理与归档和云数据备份与恢复的产品和服务。他能担任董事的资格包括25年多的投资银行家经验和投资基金经理经验，为以发展为导向的公司创造价值。他的优势是战略市场定位、融资与资本化建议、财务业绩指标与运营执行分析、商业与市场风险评估、审计监督与公开市场定位。此外，他在许多公司金融、合并与收购以及剥离交易中有战略评估、财政分析和整体管理经验，以及对私有和公共资本市场的了解。
David F. Dalvey has served as a member of Celcuity’s Board since February 2014. Mr. Dalvey has more than 30 years of experience in the fields of corporate finance and venture capital, working primarily with growth-oriented technology and life-science businesses. He has over 10 years of corporate finance advisory experience with two national investment banks, completing over 150 individual transactions. He has been the General Partner of Brightstone Venture Capital, a venture capital management company, since September 2000. Brightstone is a 25-year old venture capital management company that has raised and managed ten venture partnerships. Previously, he held management positions with R.J. Steichen and Company, an investment bank, from 1995 to 2000 The Food Fund LP, a venture capital firm, from 1992 to 1995 and Wessels, Arnold & Henderson, an investment bank, from 1987 to 1992. Mr. Dalvey served on the board of directors for Navarre Corporation now Speed Commerce, Inc. from 2009 until November 2012 on the board of managers for Blue Rock Market Neutral Fund, a mutual fund registered under the Investment Company Act of 1940 from 2000 to 2014 and on the board of directors for Digitiliti, Inc. from July 2011 until October 2012. Mr. Dalvey has significant operational exposure as a board director or advisor to many other public and privately held growth businesses and has served on these companies’ audit, strategic or governance committees, including companies such as HomeSpotter, Definity Health, AppTec Laboratories, CHF Solutions, BiteSquad, Agiliti, and Nature Vision. Mr. Dalvey received a B.S. in Business/Management Economics from University of Minnesota. - David F. Dalvey，他在公司金融和风险投资方面有28年的经验，主要就职于以发展为导向的技术公司。2008年9月至今，他担任Mount Yale Venture Fund, L.P。的管理合伙人， 该公司是一家管理公司，投资高层风险投资基金和其他资产；2000年9月至今，担任风险投资管理公司Brightstone Capita的普通合伙人。此前，1995至2000年，他在R.J. Steichen and Company担任管理职位；1992至1995年，在风险投资公司The Food Fund LP担任管理职位；1987至1992年，在投资银行Wessels, Arnold & Henderson担任管理职位。他有丰富的运营经验，曾担任多家私人公司的董事会成员或顾问，包括担任Definity Health, Inc. （直到出售给United Health Group）， NatureVision, Inc. （直到首次公开募股） 和Agiliti, Inc. （直到出售给VeriCenter, Inc./SunGard Services）的董事。目前，他担任Blue Rock Market Neutral Fund的独立董事和审计委员会成员， 该公司是在1940年投资公司法注册的共有基金；并担任Digitiliti, Inc. （OTC：DIGI.PK）的董事，该公司提供计算机数据管理与归档和云数据备份与恢复的产品和服务。他能担任董事的资格包括25年多的投资银行家经验和投资基金经理经验，为以发展为导向的公司创造价值。他的优势是战略市场定位、融资与资本化建议、财务业绩指标与运营执行分析、商业与市场风险评估、审计监督与公开市场定位。此外，他在许多公司金融、合并与收购以及剥离交易中有战略评估、财政分析和整体管理经验，以及对私有和公共资本市场的了解。
- David F. Dalvey has served as a member of Celcuity’s Board since February 2014. Mr. Dalvey has more than 30 years of experience in the fields of corporate finance and venture capital, working primarily with growth-oriented technology and life-science businesses. He has over 10 years of corporate finance advisory experience with two national investment banks, completing over 150 individual transactions. He has been the General Partner of Brightstone Venture Capital, a venture capital management company, since September 2000. Brightstone is a 25-year old venture capital management company that has raised and managed ten venture partnerships. Previously, he held management positions with R.J. Steichen and Company, an investment bank, from 1995 to 2000 The Food Fund LP, a venture capital firm, from 1992 to 1995 and Wessels, Arnold & Henderson, an investment bank, from 1987 to 1992. Mr. Dalvey served on the board of directors for Navarre Corporation now Speed Commerce, Inc. from 2009 until November 2012 on the board of managers for Blue Rock Market Neutral Fund, a mutual fund registered under the Investment Company Act of 1940 from 2000 to 2014 and on the board of directors for Digitiliti, Inc. from July 2011 until October 2012. Mr. Dalvey has significant operational exposure as a board director or advisor to many other public and privately held growth businesses and has served on these companies’ audit, strategic or governance committees, including companies such as HomeSpotter, Definity Health, AppTec Laboratories, CHF Solutions, BiteSquad, Agiliti, and Nature Vision. Mr. Dalvey received a B.S. in Business/Management Economics from University of Minnesota.
- Richard J. Nigon
-
Richard J. Nigon，自2010年2月起担任NTIC董事，自2012年11月起担任该公司非执行主席。Nigon先生是Cedar Point Capital，Inc.的高级副总裁，该公司是一家为早期企业筹集资金的私营公司。从2001年2月到2007年5月，Nigon先生担任私人控股投资公司Miller Johnson Steichen Kinnard（MJSK）的Equity Corporate Finance董事。2006年12月，MJSK被Stifel Nicolaus收购，Nigon先生是Stifel Nicolaus的私募董事总经理。2000年2月至2001年2月，Nigon先生在网络托管公司Dantis，Inc.担任首席财务官。在加入Dantis之前，Nigon先生于1970年至2000年期间受雇于Ernst & Young，LLP，并于1981年至2000年期间担任合伙人。在安永期间，Nigon先生曾担任安永双城创业服务集团的董事，并且是消费零售和制造领域多家上市公司的协调合作伙伴。除NTIC外，Nigon先生还担任Celcuity公司的董事会成员和审计委员会主席，并在多家私营公司的董事会任职。Nigon先生此前曾在Tactile Systems Technology, Inc.、Virtual Radiologic Corporation和微管医疗仪器解决方案公司的董事会任职，直至2017年2月被Teleflex Incorporated收购。
Richard J. Nigon has been a director of NTIC since February 2010 and non executive Chairman of the Board since November 2012. Mr. Nigon is the Senior Vice President of Cedar Point Capital, Inc., a private company that raises capital for early stage companies. From February 2001 until May 2007, Mr. Nigon was a Director of Equity Corporate Finance for Miller Johnson Steichen Kinnard (MJSK), a privately held investment firm. In December 2006, MJSK was acquired by Stifel Nicola, and Mr. Nigon was a Managing Director of Private Placements at Stifel Nicola. From February 2000 to February 2001, Mr. Nigon served as the Chief Financial Officer of Dantis, Inc., a b hosting company. Prior to joining Dantis, Mr. Nigon was employed by Ernst & Young, LLP from 1970 to 2000, where he served as a partner from 1981 to 2000. While at Ernst & Young, Mr. Nigon served as the Director of Ernst & Young's Twin Cities Entrepreneurial Services Group and was the coordinating partner on several publicly traded companies in the consumer retailing and manufacturing sectors. In addition to NTIC, Mr. Nigon also serves on the board of directors of Celcuity Inc. and as chairperson of its audit committee and serves on the board of directors of a number of privately held companies. Mr. Nigon previoly served on the board of directors of Tactile Systems Technology, Inc., Virtual Radiologic Corporation and Vascular Solutions, Inc. until its acquisition by Teleflex Incorporated in February 2017. - Richard J. Nigon，自2010年2月起担任NTIC董事，自2012年11月起担任该公司非执行主席。Nigon先生是Cedar Point Capital，Inc.的高级副总裁，该公司是一家为早期企业筹集资金的私营公司。从2001年2月到2007年5月，Nigon先生担任私人控股投资公司Miller Johnson Steichen Kinnard（MJSK）的Equity Corporate Finance董事。2006年12月，MJSK被Stifel Nicolaus收购，Nigon先生是Stifel Nicolaus的私募董事总经理。2000年2月至2001年2月，Nigon先生在网络托管公司Dantis，Inc.担任首席财务官。在加入Dantis之前，Nigon先生于1970年至2000年期间受雇于Ernst & Young，LLP，并于1981年至2000年期间担任合伙人。在安永期间，Nigon先生曾担任安永双城创业服务集团的董事，并且是消费零售和制造领域多家上市公司的协调合作伙伴。除NTIC外，Nigon先生还担任Celcuity公司的董事会成员和审计委员会主席，并在多家私营公司的董事会任职。Nigon先生此前曾在Tactile Systems Technology, Inc.、Virtual Radiologic Corporation和微管医疗仪器解决方案公司的董事会任职，直至2017年2月被Teleflex Incorporated收购。
- Richard J. Nigon has been a director of NTIC since February 2010 and non executive Chairman of the Board since November 2012. Mr. Nigon is the Senior Vice President of Cedar Point Capital, Inc., a private company that raises capital for early stage companies. From February 2001 until May 2007, Mr. Nigon was a Director of Equity Corporate Finance for Miller Johnson Steichen Kinnard (MJSK), a privately held investment firm. In December 2006, MJSK was acquired by Stifel Nicola, and Mr. Nigon was a Managing Director of Private Placements at Stifel Nicola. From February 2000 to February 2001, Mr. Nigon served as the Chief Financial Officer of Dantis, Inc., a b hosting company. Prior to joining Dantis, Mr. Nigon was employed by Ernst & Young, LLP from 1970 to 2000, where he served as a partner from 1981 to 2000. While at Ernst & Young, Mr. Nigon served as the Director of Ernst & Young's Twin Cities Entrepreneurial Services Group and was the coordinating partner on several publicly traded companies in the consumer retailing and manufacturing sectors. In addition to NTIC, Mr. Nigon also serves on the board of directors of Celcuity Inc. and as chairperson of its audit committee and serves on the board of directors of a number of privately held companies. Mr. Nigon previoly served on the board of directors of Tactile Systems Technology, Inc., Virtual Radiologic Corporation and Vascular Solutions, Inc. until its acquisition by Teleflex Incorporated in February 2017.
高管简历
中英对照 | 中文 | 英文- Vicky Hahne
Vicky Hahne于2017年7月加入我们的首席财务官。她拥有20多年的财务领导经验，包括最近在梦百合行业工作的10年。在加入Celcuity之前，Hahne女士于2015年至2017年担任医疗设备制造商Respiratory Technologies Inc.的财务总监。任职Respiratory Technologies公司期间，她曾在尽职调查过程中发挥关键作用，将公司出售给Koninklijke Philips公司。2014年，她担任梦百合信息技术公司Ability Network Inc.的财务总监。2007年至2012年，Hahne女士担任医疗设备后处理公司SterilMed Inc.的财务总监，她在该公司显著参与了将该公司出售给强生公司的交易。在担任这些职务之前，Hahne女士曾在SimonDelivers Inc.担任多个高级财务职位，包括首席财务官。Hahne女士在早期阶段，高增长公司拥有丰富的经验，其职责包括财务控制和管理，财务分析，合并和收购，建立基础设施和系统。她获得Northern State University的财务和会计B.S.学位，并于1990年获得注册会计师证书。
Vicky Hahne joined as our Chief Financial Officer in July 2017. She has more than 20 years of financial leadership experience, including the most recent 10 years in the healthcare industry. Prior to joining Celcuity, Ms. Hahne served as Controller of Respiratory Technologies Inc., a medical device manufacturer, from 2015 to 2017. While at Respiratory Technologies, she played a key role in the due diligence process to sell the company to Koninklijke Philips. In 2014 she served as Controller for Ability Network Inc., a healthcare information technology company. From 2007 to 2012 Ms. Hahne served as Controller of Sterilmed Inc., a medical device reprocessing company, where she was significantly involved in the sale of the company to Johnson & Johnson. Prior to these roles, Ms. Hahne held several senior financial positions at SimonDelivers Inc., including Chief Financial Officer.- Vicky Hahne于2017年7月加入我们的首席财务官。她拥有20多年的财务领导经验，包括最近在梦百合行业工作的10年。在加入Celcuity之前，Hahne女士于2015年至2017年担任医疗设备制造商Respiratory Technologies Inc.的财务总监。任职Respiratory Technologies公司期间，她曾在尽职调查过程中发挥关键作用，将公司出售给Koninklijke Philips公司。2014年，她担任梦百合信息技术公司Ability Network Inc.的财务总监。2007年至2012年，Hahne女士担任医疗设备后处理公司SterilMed Inc.的财务总监，她在该公司显著参与了将该公司出售给强生公司的交易。在担任这些职务之前，Hahne女士曾在SimonDelivers Inc.担任多个高级财务职位，包括首席财务官。Hahne女士在早期阶段，高增长公司拥有丰富的经验，其职责包括财务控制和管理，财务分析，合并和收购，建立基础设施和系统。她获得Northern State University的财务和会计B.S.学位，并于1990年获得注册会计师证书。
- Vicky Hahne joined as our Chief Financial Officer in July 2017. She has more than 20 years of financial leadership experience, including the most recent 10 years in the healthcare industry. Prior to joining Celcuity, Ms. Hahne served as Controller of Respiratory Technologies Inc., a medical device manufacturer, from 2015 to 2017. While at Respiratory Technologies, she played a key role in the due diligence process to sell the company to Koninklijke Philips. In 2014 she served as Controller for Ability Network Inc., a healthcare information technology company. From 2007 to 2012 Ms. Hahne served as Controller of Sterilmed Inc., a medical device reprocessing company, where she was significantly involved in the sale of the company to Johnson & Johnson. Prior to these roles, Ms. Hahne held several senior financial positions at SimonDelivers Inc., including Chief Financial Officer.
- Lance G. Laing
LanceG.Laing是我们的联合创始人，自2012年我们开始运营以来一直担任首席科学官，Vice President，秘书和董事。Laing博士的职业生涯跨度超过15年，从事药物发现研究和技术开发。他在约翰霍普金斯大学（Johns Hopkins University）获得生物物理学和生物化学博士学位，并在华盛顿大学医学院（Washington University Medical School）完成了美国国立卫生研究院博士后奖学金。他已获得19项美国专利，另有24项正在申请的美国专利。他的药物发现研究生涯始于诺华收购的ScriptGen/Anadys Pharmaceuticals，在那里他在Peter Kim教授（后来成为默克研究总裁）手下工作。他还担任两家公司的化学和生物应用主任以及检测产品开发主任，这两家公司各自开发了类似于Celcuity用于执行Celsignia测试的仪器。他在这两家仪器公司的工作使他在为这些仪器开发各种专利申请方面拥有独特的专业知识和经验。最近，他曾担任国际药物发现和开发公司的执行董事。
Lance G. Laing is our co-founder and has served as Chief Science Officer, Vice President, Secretary and a director since we commenced operations in 2012. Dr. Laing’s career spans more than 15 years in drug discovery research and technology development. He received his doctorate in biophysics and biochemistry from The Johns Hopkins University and completed a National Institutes of Health post-doctoral fellowship at Washington University Medical School. He has received 19 U.S. patents and has an additional 24 U.S. patents pending. His drug discovery research career began at Scriptgen/Anadys Pharmaceuticals purchased by Novartis, where he worked under Professor Peter Kim, who became President of Merck Research. He also was Director of Chemistry and Bioapplications and Director of Detection Product Development for two companies that each developed instruments similar to those Celcuity uses to perform the CELsignia tests. His work at these two instrument companies gave him unique expertise and experience in developing a variety of patented applications for these instruments. Most recently, he served as an executive director for an international drug discovery and development company.- LanceG.Laing是我们的联合创始人，自2012年我们开始运营以来一直担任首席科学官，Vice President，秘书和董事。Laing博士的职业生涯跨度超过15年，从事药物发现研究和技术开发。他在约翰霍普金斯大学（Johns Hopkins University）获得生物物理学和生物化学博士学位，并在华盛顿大学医学院（Washington University Medical School）完成了美国国立卫生研究院博士后奖学金。他已获得19项美国专利，另有24项正在申请的美国专利。他的药物发现研究生涯始于诺华收购的ScriptGen/Anadys Pharmaceuticals，在那里他在Peter Kim教授（后来成为默克研究总裁）手下工作。他还担任两家公司的化学和生物应用主任以及检测产品开发主任，这两家公司各自开发了类似于Celcuity用于执行Celsignia测试的仪器。他在这两家仪器公司的工作使他在为这些仪器开发各种专利申请方面拥有独特的专业知识和经验。最近，他曾担任国际药物发现和开发公司的执行董事。
- Lance G. Laing is our co-founder and has served as Chief Science Officer, Vice President, Secretary and a director since we commenced operations in 2012. Dr. Laing’s career spans more than 15 years in drug discovery research and technology development. He received his doctorate in biophysics and biochemistry from The Johns Hopkins University and completed a National Institutes of Health post-doctoral fellowship at Washington University Medical School. He has received 19 U.S. patents and has an additional 24 U.S. patents pending. His drug discovery research career began at Scriptgen/Anadys Pharmaceuticals purchased by Novartis, where he worked under Professor Peter Kim, who became President of Merck Research. He also was Director of Chemistry and Bioapplications and Director of Detection Product Development for two companies that each developed instruments similar to those Celcuity uses to perform the CELsignia tests. His work at these two instrument companies gave him unique expertise and experience in developing a variety of patented applications for these instruments. Most recently, he served as an executive director for an international drug discovery and development company.
- Brian F. Sullivan
Brian F. Sullivan，于2005年担任Entegris, Inc.公司董事会成员。2003年12月至公司兼并后，他担任Entegris Minnesota主管及该公司薪酬和股票期权委员会成员，公司兼并后，一直到2008年5月加入审计和财务委员会期间，他担任管理层发展和薪酬委员会成员。他于2012年联合创立生物技术公司Celcuity LLC，并担任该公司主席和CEO。2002年起他担任SterilMed, Inc公司主席和CEO，直至2011年他从该公司退休，该公司同时于2011年被Johnson & Johnson公司收购。他于1986年联合创立Recovery Engineering, Inc.公司，并担任主席和CEO，直至该公司1999年被Proctor & Gamble Co。收购。他于2008年担任Virtual Radiologic Corporation董事会成员，直至该公司2010年被收购。他还担任多家私人公司和非盈利机构的董事会成员。他在哈佛大学（Harvard University）获得学士学位。
Brian F. Sullivan is our co-founder and has served as Chairman of the Board and Chief Executive Officer since we commenced operations in 2012. Mr. Sullivan has over 25 years of experience founding and building successful, high growth technology companies. He was Chairman and CEO of SterilMed, a medical device reprocessing company, from 2003 when he led an investment group to acquire a majority interest, until its sale to Ethicon Endo-Surgery Inc., a Johnson & Johnson company, for $330 million in 2011. Previously, he was co-founder and Chief Executive Officer of Recovery Engineering, a filtration company, which he took public and subsequently sold to Procter & Gamble for $265 million in 1999. Since 2003 Mr. Sullivan has served on the board of directors of Entegris, Inc., a publicly-held company. Mr. Sullivan has received seven U.S. patents and has several patents pending. He graduated magna cum laude with distinction from Harvard College with an A.B. in economics.- Brian F. Sullivan，于2005年担任Entegris, Inc.公司董事会成员。2003年12月至公司兼并后，他担任Entegris Minnesota主管及该公司薪酬和股票期权委员会成员，公司兼并后，一直到2008年5月加入审计和财务委员会期间，他担任管理层发展和薪酬委员会成员。他于2012年联合创立生物技术公司Celcuity LLC，并担任该公司主席和CEO。2002年起他担任SterilMed, Inc公司主席和CEO，直至2011年他从该公司退休，该公司同时于2011年被Johnson & Johnson公司收购。他于1986年联合创立Recovery Engineering, Inc.公司，并担任主席和CEO，直至该公司1999年被Proctor & Gamble Co。收购。他于2008年担任Virtual Radiologic Corporation董事会成员，直至该公司2010年被收购。他还担任多家私人公司和非盈利机构的董事会成员。他在哈佛大学（Harvard University）获得学士学位。
- Brian F. Sullivan is our co-founder and has served as Chairman of the Board and Chief Executive Officer since we commenced operations in 2012. Mr. Sullivan has over 25 years of experience founding and building successful, high growth technology companies. He was Chairman and CEO of SterilMed, a medical device reprocessing company, from 2003 when he led an investment group to acquire a majority interest, until its sale to Ethicon Endo-Surgery Inc., a Johnson & Johnson company, for $330 million in 2011. Previously, he was co-founder and Chief Executive Officer of Recovery Engineering, a filtration company, which he took public and subsequently sold to Procter & Gamble for $265 million in 1999. Since 2003 Mr. Sullivan has served on the board of directors of Entegris, Inc., a publicly-held company. Mr. Sullivan has received seven U.S. patents and has several patents pending. He graduated magna cum laude with distinction from Harvard College with an A.B. in economics.